Investor Presentation

Curt R. Hartman
President & Chief Executive Officer
Luke A. Pomilio
Chief Financial Officer

May 2017
Forward-Looking Information
This presentation contains forward-looking statements based on certain assumptions
and contingencies that involve risks and uncertainties. The forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and relate to the Company's performance on a going-forward basis.
The forward-looking statements in this presentation involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially from those
expressed in the forward-looking statements herein or in previous disclosures. In
addition to general industry and economic conditions, factors that could cause actual
results to differ materially from those discussed in the forward-looking statements in this
presentation include, but are not limited to the risks relating to forward-looking
statements discussed in the Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2016.

Management has disclosed adjusted financial measurements in this presentation that

present financial information that is not in accordance with generally accepted
accounting principles (GAAP). These adjusted financial measures are helpful to
management in comparing the recurring aspects of the business performance without
the effect of unusual, non-recurring or special revenues or costs. These measurements
are not a substitute for GAAP measurements. Investors should consider adjusted
measures in addition to, and not as a substitute for, or superior to, financial performance
measures prepared in accordance with GAAP.

2
Company Snapshot
Company Overview Global Presence

n Founded in 1970 in Utica, NY, CONMED is a global medical technology organization with n Direct sales to 17 countries and indirect
~3,300 employees and sales across six continents sales to more than 100 countries

Key Business Categories Employees by Region

Revenue by Category Orthopedic Surgery

OUS 1,250
n Surgical devices including capital, 38%
disposables, and implants used in the
55%
repair of soft tissue and joint injuries
US 2,050
62%
45%
General Surgery
Total Employees: 3,300
n Low Impact Laparoscopy, enabled by
the AirSeal System Revenue by Region

n GI diagnostic and therapeutic Europe

products 19%

n ECG and other patient care devices

Americas
Ex-US
Orthopedic Surgery General Surgery US 52% 11%

2016 Actual All Other

18%
2016 Actual

3
Q1 2017 Results and 2017 Guidance
Q1 2017

Reported Revenue: $186.6M

3.0% reported growth, 3.7% growth in constant currency
Adjusted EPS1: $0.38

Comments on Q1 2017
Domestic sales growth of 3.5%, resulting from a strong performance in General Surgery,
partially offset by a decline in Orthopedics
International constant currency growth of 3.9%, with sales growth across both reporting
categories

2017 Full Year Guidance

Constant currency growth of 1% to 3%
FX headwind on sales versus 2016 of approximately 0.5% (based on exchange rates as of
April 21, 2017)
Adjusted EPS1: $1.85 to $1.95

1Excludes the after-tax costs of special items including acquisitions, litigation and restructuring, as well as amortization of intangible assets, net of tax.

4
Orthopedics Overview
Description Global Market/Key Competitors
Devices for repair of soft tissue injuries in $4.4 to $4.6 Billion
joints, particularly the knee and shoulder Arthrex
Sports Medicine DePuy Mitek (J&J)
Smith & Nephew
Stryker

Surgical drills and saws powered by $1.4 to $1.6 Billion

battery, electricity, or pneumatic with Stryker
related single-use cutting accessories DePuy Synthes (J&J)
Powered Instruments Medtronic (Midas Rex / Xomed)
Zimmer
MicroAire

MTF allograft tissue used in sports $375 to $425 Million

medicine surgery Allosource
Allograft Tissue LifeNet
RTI

High definition surgical visualization $1.8 to $2.0 Billion

systems to enable minimally invasive Stryker
arthroscopic surgery Arthrex
Surgical Visualization Karl Storz
Olympus
Richard Wolf
Smith & Nephew

Revenue Split Revenue Composition Selling Model

41% US 73% Single-Use Items US - Hybrid Sales Model
59% International Intl - Direct in 16 Countries

5
General Surgery Overview
Description Global Market/Key Competitors
A platform of devices and accessories to $1.4 to $1.6 Billion
create and enter the surgical working Ethicon (J&J) Medtronic (Covidien)
space in minimally invasive procedures Applied Medical
Access Stryker
Karl Storz
Olympus

Devices using Radio Frequency (RF) $2.6 to $2.8 Billion

energy to affect tissue by cutting, sealing, Medtronic (Covidien) Olympus
Energy or causing hemostasis in open or Ethicon (J&J) Megadyne
minimally invasive procedures ERBE

Instruments and accessories for $1.5 to $1.7 Billion

minimally invasive laparoscopic, open, Karl Storz CR Bard
Instruments and robotic approaches Aesculap Cooper Surgical
Stryker
Ethicon (J&J)

Therapeutic and diagnostic endoscopic $3.0 to $3.2 Billion

Endoscopic products used by Gastroenterologists Boston Scientific Olympus
Cook Medical Merit Endotek
Technologies
Cantel STERIS

Single-use devices for monitoring cardiac $0.8 to $1.0 Billion

activity and other patient care devices 3M Company
Critical Care Medtronic (Covidien)

Revenue Split Revenue Composition Selling Model

67% US 88% Single-Use Items US - Direct Sales Model
33% International Intl - Direct in 4 Countries

6
Growth Through People and Products
2015
Phase One
People
Eight of ten directors appointed post-2013
New CEO effective November 2014
Leadership team reconstituted with new commercial
leaders in every business; six of ten leaders new to
company since November 2014
Sales and marketing leadership restructured across all
businesses; teams substantially rebuilt
Restored Business Development function to drive
acquisition strategy
International Direct and Export management structure
revised; numerous leadership transitions across key
geographies
7
2016
Phase Two
Products
New marketing teams developed product roadmap
strategies for each business
Existing projects evaluated and either refocused or
terminated
SurgiQuest acquisition provided innovation jumpstart to
Advanced Surgical business
R&D function restructured under Kurt Azarbarzin,
CONMEDs newly appointed Corporate VP of R&D
Continued to aggressively pursue business
development opportunities to secure innovative
technologies and fill product portfolio gaps
Aligned manufacturing, advanced engineering, RA and
QA to support new product launch agenda
Leadership Team
COMMERCIAL FUNCTIONAL
Years at Years in Years at Years in
Executive Title CONMED Industry Executive Title CONMED Industry
Curt President & 2 26 Luke EVP & CFO 21 21
Hartman CEO Pomilio

Pat President, 2 26 Heather EVP, 15 15

Beyer International Cohen Human
Resources
Bill VP/GM, 2 14 Dan EVP & 18 18
Peters Advanced Jonas General
Surgical Counsel
Jed VP/GM, 4 31 Wilfredo EVP, 1 24
Kennedy Endoscopic Ruiz-Caban RA/QA and
Technologies Operations
Nate VP/GM, 1 16
Folkert Orthopedics
Peter EVP, 2 21
Shagory Corporate
Development
and Strategy

8
CONMEDs Innovation Journey

2014 and Prior 2015/2016

Existing projects evaluated and either refocused

Product development strategy not focused or or abandoned; refocused projects released in
market driven 2016 include EDGE and Helix

Limited innovation in core businesses; Business development approach established to

substantial investments in non-core accelerate innovation offering and pursue
opportunities strategic additions

Project budgets and timetables lacked Strategic planning process completed; new
accountability commercial, marketing, and R&D leaders own
product roadmap strategy and execution
Market acceptance of released products was
limited R&D departments restructured under new leader

Manufacturing, RA/QA, and support teams

focused on ensuring support and alignment from
development through product lifecycle

Marketing-driven product development becoming a meaningful

component of the Companys commercial strategy
9
Inorganic Growth Complements Organic Pipeline

ACCESS PORT iFS TRI-LUMEN TUBING

Patented, Revolutionary Replaces standard insufflation and Industrys Only
Valve-Free Design smoke evacuation machines in the Tri-Lumen Tubing
OR Patented, tri-lumen
Creates invisible pressure
barrier with no valves,
Offers AirSeal, Smoke Evac, and design
gaskets, or seals standard insufflation modes Pumps in CO2
Real-time pressure sensing Evacuates smoke out
Enables real-time pressure Measures pressure in
sensing dynamically responds to changes in
abdominal environment real time
Vents abdominal
overpressures
Enables intact specimen
removal & integrated smoke
evacuation

AirSeal is the most technologically advanced and only integrated access management system
for robotic and laparoscopic surgery, enabling numerous clinical benefits with the low impact
laparoscopy approach

10
AirSeal Domestic and Global Market
Domestic Procedure Market
Robotic Surgery (2014) ~450,000

Laparoscopic Surgery (2015) ~2,890,000

~ $568 Million in Annual Disposables ~6,700 Capital Units Required*

Global Procedure Market

Robotic Surgery (2014) ~ 600,000

Laparoscopic Surgery (2015) ~11,000,000

~ $2 Billion in Annual Disposables

~23,000 Capital Units Required*

AirSeal penetration is approximately 20% in global robotic procedures

Clinical data continues to strengthen adoption

* 2 Procedures per day per Capital Unit

11
Commercial Progress
International Sales Growth (constant currency)
Driving One CONMED approach
8.0%

Leadership restructuring complete 6.0%

4.0%
Concentrated effort in key direct
markets to increase existing product 2.0%

registration investments and

0.0%
accountability
-2.0%

Organic growth trend supported by -4.0%

limited impact from SurgiQuest Q116* Q216* Q316* Q416* Q117

acquisition
*Proforma growth inclusive of 2015 AirSeal revenue

AirSeal still in early stages in

International markets - 2nd year in
most markets

International Sales represent 48% of consolidated sales for 2016. International business split: Direct 2/3, Export 1/3

12
Commercial Progress
Domestic Orthopedics Sales Growth
Mixed performance
Procedure specific
2.0%
consistently positive
Arthroscopy Enabling Devices 0.0%

(resection, fluid) challenged; -2.0%

EDGE system should help -4.0%

stabilize -6.0%
Capital results mixed
-8.0%
Focus on the MTF opportunity
-10.0%

Focus on sales execution and sales -12.0%

channel -14.0%

-16.0%
Account access and contract Q116 Q216 Q316 Q416 Q117

strategy in progress

New products critical to success

Domestic Orthopedics represents 22% of consolidated sales for 2016

13
Commercial Progress
Domestic General Surgery Sales Growth

Continuity in leadership and business 10.0%

plans 9.0%
8.0%
7.0%
Fully integrated SurgiQuest acquisition
6.0%
within Advanced Surgical
5.0%
4.0%
New products and expanded sales 3.0%
force showing immediate impact in 2.0%
Endoscopic Technologies 1.0%
0.0%
Q116* Q216* Q316* Q416* Q117
AirSeal is a truly differentiated
platform technology *Proforma growth inclusive of 2015 AirSeal revenue

Domestic General Surgery represents 30% of consolidated sales for 2016

14
CONMED vs Market Growth Rates

Market CONMED
Growth Revenue 2016
Rate % Trend Comments

Positive organic constant currency growth

International 2 4% 48% Accelerating Advanced Surgical organic growth
Strengthened presence in key markets direct and export

AirSeal platform in early innings

Domestic CET category enabling further expansion
2 - 4% 30% New products and sales force expansion continues across
General Surgery
category
Weakness in Arthroscopy Enabling Devices a long-term
issue; EDGE will begin to slow erosion
Domestic Innovation focus critical to reverse declines
4 - 6% 22% Account access and sales execution are high priority areas
Orthopedics
of focus

Return to market growth and accelerate

15
Financial Goal - EBITDA

EBITDA Margin Trend

Despite limited sales growth since 2013,
EBITDA margin has expanded (exclusive of the
impact of FX); driving sales growth remains the
top priority
EBITDA margin for 2016 would be approximately
350 bps higher than presented using 2013
average FX rates

EBITDA Margin Strategy

Drive incremental sales through existing SG&A
Adjusted EBITDA margin - Using 2016 Average FX Rates structure over consolidated footprint
Reallocate investments to areas with highest
returns; pipeline priorities now reflect enhanced
margin profile expectations
Implement manufacturing and procurement cost
savings programs

Continue to pursue margin expansion; move

margins in line with industry peer group

16
2017 Priorities

Focus on reinvigorating product portfolio organic and inorganic

Orthopedics Drive EDGE adoption and stabilize Arthro Power Portfolio
Salesforce execution and contract access

Capitalize on organization stability pursue synergy sales

Expand AirSeal into laparoscopic market
General Surgery Continue to reinvigorate product portfolio
Continue CET growth progress

Build on growing sales momentum and investments in talent; further

advance One CONMED approach
International Continue to leverage sales channel optimization opportunities
Continue to build export market support

Implement manufacturing and procurement cost savings programs

Other Execute on product development plans
Continue to pursue inorganic growth opportunities

17
Closing Thoughts

P We remain focused on improving our overall operating

performance
P Our General Surgery and International Businesses are
on track; Domestic Orthopedic performance has more
work ahead
P New product innovation is critical to our growth plan
P 2017 will bring continued enhancements to the business
and our outcomes
P We have made important strides in our turnaround, and
I am proud of the work of this leadership team

18
Destination of Choice

Talented employees, customers, and investors!

19